Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of CNTO 3649 in Healthy Men and T2DM Patients
NCT02224118Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2009
- Primary completion
- Mar 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CNTO-3649 in type 2 diabetes mellitus (T2DM) (7 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Treatment-Emergent Adverse Events. Started Jul 2009; status: completed.
02
Drugs
CNTO-3649
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02224118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02224118.